Cost-effectiveness analysis of sacubitril/valsartan vs enalapril in patients with heart failure and reduced ejection fraction

JAMA Cardiology

Volumn 1, Issue 6, 2016, Pages 666-672

  Gaziano, Thomas A ^a   Fonarow, Gregg C ^b   Claggett, Brian ^a   Chan, Wing W ^c   Deschaseaux Voinet, Celine ^c   Turner, Stuart J ^c   Rouleau, Jean L ^d   Zile, Michael R ^e,f   McMurray, John J V ^g   Solomon, Scott D ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

^d MONTREAL HEART INSTITUTE   (Canada)

^e MEDICAL UNIVERSITY OF SOUTH CAROLINA   (United States)

^f RALPH H JOHNSON VA MEDICAL CENTER   (United States)

^g UNIVERSITY OF GLASGOW   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ENALAPRIL; SACUBITRIL PLUS VALSARTAN; AMINOBUTYRIC ACID DERIVATIVE; ANGIOTENSIN RECEPTOR ANTAGONIST; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; TETRAZOLE DERIVATIVE; VALSARTAN;

ADULT; ALL CAUSE MORTALITY; ARTICLE; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DOUBLE BLIND PROCEDURE; DRUG COST; HEALTH CARE COST; HEART FAILURE WITH REDUCED EJECTION FRACTION; HOSPITAL ADMISSION; HOSPITAL COST; HOSPITALIZATION; HUMAN; MAJOR CLINICAL STUDY; MEDICARE; MIDDLE AGED; MORTALITY; PRIORITY JOURNAL; PRIVATE HEALTH INSURANCE; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REIMBURSEMENT; SENSITIVITY ANALYSIS; UNITED STATES; COST BENEFIT ANALYSIS; ECONOMICS; FEMALE; HEART FAILURE; HEART STROKE VOLUME; MALE; PATHOPHYSIOLOGY;

AMINOBUTYRATES; ANGIOTENSIN RECEPTOR ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; COST-BENEFIT ANALYSIS; ENALAPRIL; FEMALE; HEART FAILURE; HUMANS; MALE; MIDDLE AGED; QUALITY OF LIFE; STROKE VOLUME; TETRAZOLES; VALSARTAN;

EID: 85021122971     PISSN: 23806583     EISSN: 23806591     Source Type: Journal    
DOI: 10.1001/jamacardio.2016.1747     Document Type: Article

References (35)

1. Mozaffarian D, Benjamin EJ, Go AS, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2015 update: a report from the American Heart Association. Circulation. 2015; 131(4):e29-e322.
2. Heidenreich PA, Trogdon JG, Khavjou OA, et al; American Heart Association Advocacy Coordinating Committee; Stroke Council; Council on Cardiovascular Radiology and Intervention; Council on Clinical Cardiology; Council on Epidemiology and Prevention; Council on Arteriosclerosis; Thrombosis and Vascular Biology; Council on Cardiopulmonary; Critical Care; Perioperative and Resuscitation; Council on Cardiovascular Nursing; Council on the Kidney in Cardiovascular Disease; Council on Cardiovascular Surgery and Anesthesia, and Interdisciplinary Council on Quality of Care and Outcomes Research. Forecasting the future of cardiovascular disease in the United States: a policy statement from the American Heart Association. Circulation. 2011;123(8):933-944.
3. McMurray JJ, Packer M, Desai AS, et al; PARADIGM-HF Investigators and Committees. Angiotensin-neprilysin inhibition vs enalapril in heart failure. N Engl J Med. 2014;371(11):993-1004.
4. Packer M, McMurray JJ, Desai AS, et al; PARADIGM-HF Investigators and Coordinators. Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure. Circulation. 2015;131(1):54-61.
5. Chan DC, Heidenreich PA, Weinstein MC, Fonarow GC. Heart failure disease management programs: a cost-effectiveness analysis. Am Heart J. 2008;155(2):332-338.
6. Delea TE, Vera-Llonch M, Richner RE, Fowler MB, Oster G. Cost effectiveness of carvedilol for heart failure. Am J Cardiol. 1999;83(6):890-896.
7. Gaziano TA. Cardiovascular disease in the developing world and its cost-effective management. Circulation. 2005;112(23):3547-3553.
8. McMurray JJ, Packer M, Desai AS, et al; PARADIGM-HF Committees and Investigators. Dual angiotensin receptor and neprilysin inhibition as an alternative to angiotensin-converting enzyme inhibition in patients with chronic systolic heart failure: rationale for and design of the Prospective comparison of ARNI with ACEI to Determine Impact on Global Mortality and morbidity in Heart Failure trial (PARADIGM-HF). Eur J Heart Fail. 2013;15(9): 1062-1073.
9. DRG Expert 2014. Salt Lake City, Utah: OPTUMInsight; 2014.
10. Ziaeian B, Sharma PP, Yu TC, Johnson KW, Fonarow GC. Factors associated with variations in hospital expenditures for acute heart failure in the United States. Am Heart J. 2015;169(2):282-289.e15.
11. Agency for Healthcare Research and Quality (AHRQ). Medical expenditure panel survey public use file. 2012; http://meps.ahrq.gov/data_stats/download_data_files_detail.jsp?cboPufNumber=HC-036. Accessed January 23, 2015.
12. Pfuntner A, Wier LM, Elixhauser A. Overview of Hospital Stays in the United States, 2011. http://www.hcup-us.ahrq.gov/reports/statbriefs/sb166.pdf. Published November 2013. Accessed May 17, 2016.
13. Thomson Healthcare. Red Book Montvale. NJ: Thomson PDR; 2014.
14. Gold MR, Siegel JE, Russell LB, Weinstein MC. Cost-Effectiveness in Health and Medicine. Oxford: Oxford University Press; 1996.
15. Claggett B, Packer M, McMurray JJ, et al; PARADIGM-HF Investigators. Estimating the long-term treatment benefits of sacubitril-valsartan. N Engl J Med. 2015;373(23):2289-2290.
16. O’Sullivan AK, Rubin J, Nyambose J, Kuznik A, Cohen DJ, Thompson D. Cost estimation of cardiovascular disease events in the US. Pharmacoeconomics. 2011;29(8):693-704.
17. Hunink MM, Weinstein MC, Wittenberg E, et al. Decision Making in Health and Medicine: Integrating Evidence and Values. 2nd ed. Cambridge, United Kingdom: Cambridge University Press; 2014.
18. Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB. Recommendations of the Panel on Cost-effectiveness in Health and Medicine. JAMA. 1996;276(15):1253-1258.
19. Neumann PJ, Cohen JT, Weinstein MC. Updating cost-effectiveness—the curious resilience of the $50 000-per-QALY threshold. N Engl J Med. 2014;371(9):796-797.
20. Briggs AH. Handling uncertainty in cost-effectiveness models. Pharmacoeconomics. 2000;17(5):479-500.
21. Tiller D, Russ M, Greiser KH, et al. Prevalence of symptomatic heart failure with reduced and with normal ejection fraction in an elderly general population-the CARLA study. PLoS One. 2013;8(3): e59225.
22. Lewis EF, Lamas GA, O’Meara E, et al; CHARM Investigators. Characterization of health-related quality of life in heart failure patients with preserved versus low ejection fraction in CHARM. Eur J Heart Fail. 2007;9(1):83-91.
23. Ollendorf Daniel A, Sandhu AT, Chapman R, et al. CardioMEMS HF System (St. Jude Medical, Inc.) and Sacubitril/Valsartan (Entresto, Novartis AG) for Management of Congestive Heart Failure: Effectiveness, Value, and Value-Based Price Benchmarks. Boston, MA: Institute for Clinical and Economic Review; 2015.
24. Prosser LA, Stinnett AA, Goldman PA, et al. Cost-effectiveness of cholesterol-lowering therapies according to selected patient characteristics. Ann Intern Med. 2000;132(10):769-779.
25. Franco OH, Peeters A, Looman CWN, Bonneux L. Cost effectiveness of statins in coronary heart disease. J Epidemiol Community Health. 2005;59 (11):927-933.
26. Huse DM, Russell MW, Miller JD, et al. Cost-effectiveness of statins. Am J Cardiol. 1998;82(11):1357-1363.
27. Sanders GD, Hlatky MA, Owens DK. Cost-effectiveness of implantable cardioverter-defibrillators. N Engl J Med. 2005;353(14):1471-1480.
28. Nichol G, Kaul P, Huszti E, Bridges JF. Cost-effectiveness of cardiac resynchronization therapy in patients with symptomatic heart failure. Ann Intern Med. 2004;141(5):343-351.
29. Fearon WF, Shilane D, Pijls NHJ, et al. Cost-effectiveness of percutaneous coronary intervention in patients with stable coronary artery disease and abnormal fractional flow reserve. Circulation. 2013;128(12):1335-1340.
30. Rohde LE, Bertoldi EG, Goldraich L, Polanczyk CA. Cost-effectiveness of heart failure therapies. Nat Rev Cardiol. 2013;10(6):338-354.
31. Allen LA, Yager JE, Funk MJ, et al. Discordance between patient-predicted and model-predicted life expectancy among ambulatory patients with heart failure. JAMA. 2008;299(21):2533-2542.
32. Joffe SW, Webster K, McManus DD, et al. Improved survival after heart failure: a community-based perspective. J Am Heart Assoc. doi:10.1161/JAHA.113.000053.
33. Stewart S, MacIntyre K, Hole DJ, Capewell S, McMurray JJV. More “malignant” than cancer? five-year survival following a first admission for heart failure. Eur J Heart Fail. 2001;3(3):315-322.
34. Anderson JL, Heidenreich PA, Barnett PG, et al; ACC/AHA Task Force on Performance Measures; ACC/AHA Task Force on Practice Guidelines. ACC/AHA statement on cost/value methodology in clinical practice guidelines and performance measures: a report of the American College of Cardiology/American Heart Association Task Force on Performance Measures and Task Force on Practice Guidelines. Circulation. 2014;129(22):2329-2345.
35. King JB, Shah RU, Bress AP, Nelson RE, Bellows BK. Cost-effectiveness of sacubitril-valsartan combination therapy compared with enalapril for the treatment of heart failure with reduced ejection fraction. JACC Heart Fail. 2016;4(5):392-402.